Background: This study investigates the influence of NRAS mutation on medical results and pathological features in patients diagnosed with cutaneous melanoma. Melanoma is very dangerous form of skin cancer having very complex molecular landscape, and NRAS mutations are frequently observed in this context. Through a comprehensive analysis of patient data, including clinical records and pathological features, this research aims to elucidate effectof NRAS mutation on disease progression, survival rates, and tumor characteristics. Methods: In this prospective cohort research involving 264 individuals having cutaneous melanoma, effectof NRAS mutations on pathological features and medical result was compared to tumors containing BRAFV600E mutations and tumors without either mutation. Clinical outcome data were collected, and NRAS and BRAFV600E mutations were detected and confirmed through PCR and sequencing. Cox proportional hazards regression analysis remained led to measure association among NRAS and BRAF mutations and clinical outcomes. Results: The findings showed that 80% of NRAS mutations occurred in tumors larger than 1 mm (compared to 42% for BRAFV600E and 35% for wild type tumors), and 76% of NRAS mutations exhibited more than 2 mitosis per square millimeter (compared to 42% for BRAFV600E and 56% for wild type tumors). Multivariate analysis demonstrated that NRAS mutations, but not BRAFV600E mutations, remained linked with adverse prognostic factors for melanoma-specific survival (hazard ratio of 2.97, p-value of 0.03). NRAS mutations were also linked to thicker tumors and higher mitotic rates, independent of BRAFV600E mutations, and were correlated with shorter melanoma-specific survival. Conclusion: Findings from this study may provide valuable insights into prognostic importance of NRAS mutation in cutaneous melanoma, contributing to improved risk stratification and tailored therapeutic approaches for patients.